TAK-020

• CAT Number: I045342
• CAS Number: 1627603-21-7
• Molecular Formula: C18H17N5O3
• Molecular Weight: 351.36
• Purity: ≥95%
• Synonyms: 3-[1-[(3S)-1-prop-2-enoylpyrrolidin-3-yl]oxyisoquinolin-3-yl]-1,4-dihydro-1,2,4-triazol-5-one
• InChI: InChI=1S/C18H17N5O3/c1-2-15(24)23-8-7-12(10-23)26-17-13-6-4-3-5-11(13)9-14(19-17)16-20-18(25)22-21-16/h2-6,9,12H,1,7-8,10H2,(H2,20,21,22,25)/t12-/m0/s1
• InChIKey: HIMUHMBGRATXMK-LBPRGKRZSA-N
• SMILES: C=CC(=O)N1CCC(C1)OC2=NC(=CC3=CC=CC=C32)C4=NNC(=O)N4

TAK‑020 (Cat No.: I045342) is a potent, orally administered covalent inhibitor of Bruton’s tyrosine kinase (BTK), developed by Takeda Pharmaceuticals. It was designed using fragment‑based drug discovery and specifically targets the catalytic cysteine of BTK, achieving high selectivity over other kinases. TAK‑020 is active in immune signaling pathways, blocking B‑cell receptor and Fc ε RI‑mediated activation, and was tolerated in Phase I trials in healthy volunteers, with sustained >80% BTK occupancy and >80% basophil response reduction. It has potential therapeutic application in autoimmune disorders like rheumatoid arthritis and hematologic malignancies.

Reference

[1]. Sabat M, et al. Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64(17):12893-12902.
[Content Brief]